Posted in | News | Semiconductor | Business

ATMI Contracts with Pall to Sell ATMI Life Sciences

ATMI, Inc., a global technology company and leader in single-use bioprocess solutions, announced today it has reached agreement with Pall Corporation to sell ATMI LifeSciences in a transaction valued at $185 million.

The transaction includes all assets associated with the LifeSciences business, including two locations in Belgium plus a shared facility in Minnesota. ATMI expects the transaction to close during the first quarter of 2014, subject to applicable regulatory approvals and customary closing conditions. After tax cash proceeds from the transaction are expected to be approximately $165 million.

"We are very happy to have Pall as the new owner of this business, and believe the fit with Pall's capabilities will accelerate its growth and provide great customer support," said Chief Executive Officer, Doug Neugold. "This transaction, a result of our ongoing exploration of strategic alternatives, also has the effect of realizing significant value for our shareholders."

"The combination of ATMI LifeSciences and Pall will provide leading technology to serve the bioprocessing industry," added Senior Vice President and General Manager of ATMI LifeSciences, Mario Philips. "I'm extremely excited about joining forces with an outstanding organization like Pall Corporation and the expanded opportunities this will provide to our customers."

Barclays Capital is acting as financial advisor and Weil, Gotshal & Manges LLP is acting as legal advisor to ATMI in connection with this transaction.

About ATMI

ATMI, Inc. is a global provider of specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the microelectronics, life sciences, and other industries. For more information, please visit

About ATMI LifeSciences

ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world. For more information, please visit

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Follow us on Twitter @PallCorporation or visit



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Pall Corporation. (2019, February 08). ATMI Contracts with Pall to Sell ATMI Life Sciences. AZoM. Retrieved on November 29, 2021 from

  • MLA

    Pall Corporation. "ATMI Contracts with Pall to Sell ATMI Life Sciences". AZoM. 29 November 2021. <>.

  • Chicago

    Pall Corporation. "ATMI Contracts with Pall to Sell ATMI Life Sciences". AZoM. (accessed November 29, 2021).

  • Harvard

    Pall Corporation. 2019. ATMI Contracts with Pall to Sell ATMI Life Sciences. AZoM, viewed 29 November 2021,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback